Clonal Hematopoiesis and Its Impact on Cardiovascular Disease.

A number of recent epidemiological studies have associated the clonal expansion of hematopoietic cells, a process referred to as clonal hematopoiesis, with increased mortality. Clonal hematopoiesis increases the risk of hematological cancer, but this overall risk cannot account for the increase in mortality in the general population. Surprisingly, these mutations have also been associated with higher rates of cardiovascular disease, suggesting a previously unrecognized link between somatic mutations in hematopoietic cells and chronic disease. Here, we review recent epidemiological and experimental studies on clonal hematopoiesis that relate to cardiovascular disease.

[1]  M. J. Peebles Relationship , 2020, Definitions.

[2]  John G Doench,et al.  PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. , 2018, Blood.

[3]  M. Dubé,et al.  Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A. , 2018, Blood.

[4]  K. Ballman,et al.  Somatic mutations precede acute myeloid leukemia years before diagnosis , 2018, Nature Medicine.

[5]  Paolo Vineis,et al.  Prediction of acute myeloid leukaemia risk in healthy individuals , 2018, Nature.

[6]  O. Abdel-Wahab,et al.  Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation , 2018, The Journal of experimental medicine.

[7]  Tom Lenaerts,et al.  Evolutionary dynamics of paroxysmal nocturnal hemoglobinuria , 2018, PLoS Comput. Biol..

[8]  R. Handsaker,et al.  Insights about clonal hematopoiesis from 8,342 mosaic chromosomal alterations , 2018, Nature.

[9]  K. Walsh,et al.  CRISPR-Mediated Gene Editing to Assess the Roles of Tet2 and Dnmt3a in Clonal Hematopoiesis and Cardiovascular Disease , 2018, Circulation research.

[10]  S. Mccarroll,et al.  Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms , 2018, Science Translational Medicine.

[11]  Markus G. Manz,et al.  Molecular Minimal Residual Disease in Acute Myeloid Leukemia , 2018, The New England journal of medicine.

[12]  P. Libby,et al.  Roles of PAD4 and NETosis in Experimental Atherosclerosis and Arterial Injury: Implications for Superficial Erosion , 2018, Circulation research.

[13]  D. Goukassian,et al.  Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1β/NLRP3 Inflammasome. , 2018, Journal of the American College of Cardiology.

[14]  K. Walsh,et al.  Somatic Mutations and Clonal Hematopoiesis: Unexpected Potential New Drivers of Age-Related Cardiovascular Disease , 2018, Circulation research.

[15]  R. Levine,et al.  Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. , 2018, Cell stem cell.

[16]  Christopher A. Miller,et al.  Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential , 2018, Nature Communications.

[17]  B. Göttgens,et al.  From haematopoietic stem cells to complex differentiation landscapes , 2018, Nature.

[18]  Peter J. Park,et al.  Aging and neurodegeneration are associated with increased mutations in single human neurons , 2017, Science.

[19]  P. Libby,et al.  Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial , 2017, The Lancet.

[20]  Y. Hayashi,et al.  Expansion of EPOR-negative macrophages besides erythroblasts by elevated EPOR signaling in erythrocytosis mouse models , 2017, Haematologica.

[21]  Raquel S. Sevilla,et al.  Exome-wide association study of plasma lipids in >300,000 individuals , 2017, Nature Genetics.

[22]  Scott W. Lowe,et al.  Putting p53 in Context , 2017, Cell.

[23]  M. Ladanyi,et al.  Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. , 2017, Cell stem cell.

[24]  Christopher A. Miller,et al.  Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies. , 2017, The Journal of clinical investigation.

[25]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[26]  Kari Stefansson,et al.  Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. , 2017, Blood.

[27]  T. Hsiao,et al.  The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model , 2017, Journal of Hematology & Oncology.

[28]  M. Nahrendorf,et al.  Flow Perturbation Mediates Neutrophil Recruitment and Potentiates Endothelial Injury via TLR2 in Mice: Implications for Superficial Erosion , 2017, Circulation research.

[29]  S. Gabriel,et al.  Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease , 2017, The New England journal of medicine.

[30]  A. Mead,et al.  Myeloproliferative neoplasm stem cells. , 2017, Blood.

[31]  Matthew A. Cooper,et al.  Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice , 2017, Science.

[32]  C. Balestrieri,et al.  Dnmt3a restrains mast cell inflammatory responses , 2017, Proceedings of the National Academy of Sciences.

[33]  B. Schraven,et al.  JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1 , 2017, Leukemia.

[34]  A. LaCasce,et al.  Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Teixeira,et al.  Truncating and missense PPM1D mutations in early‐onset and/or familial/hereditary prostate cancer patients , 2016, Genes, chromosomes & cancer.

[36]  B. Ebert,et al.  The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia , 2016, Nature Reviews Cancer.

[37]  O. Abdel-Wahab,et al.  The Role of Additional Sex Combs-Like Proteins in Cancer. , 2016, Cold Spring Harbor perspectives in medicine.

[38]  Nicholas Eriksson,et al.  Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. , 2016, Blood.

[39]  T. Druley,et al.  Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults , 2016, Nature Communications.

[40]  M. Rivas,et al.  Mosaic mutations in blood DNA sequence are associated with solid tumor cancers , 2016, bioRxiv.

[41]  Wei Li,et al.  DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells , 2016, Nature Genetics.

[42]  Xia Li,et al.  Methyltransferase Dnmt3a upregulates HDAC9 to deacetylate the kinase TBK1 for activation of antiviral innate immunity , 2016, Nature Immunology.

[43]  K. Nakayama,et al.  Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels. , 2016, Experimental hematology.

[44]  T. Walsh,et al.  Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma. , 2016, JAMA oncology.

[45]  T. Rando,et al.  Stem cells and healthy aging , 2015, Science.

[46]  Xia Li,et al.  Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 , 2015, Nature.

[47]  D. Belsky,et al.  Quantification of biological aging in young adults , 2015, Proceedings of the National Academy of Sciences.

[48]  M. Hebrok,et al.  DNA methylation directs functional maturation of pancreatic β cells. , 2015, The Journal of clinical investigation.

[49]  H. Lähdesmäki,et al.  Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1–BAP1 complex , 2015, Nature Communications.

[50]  V. Fuster,et al.  Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study , 2015, Circulation.

[51]  P. Libby,et al.  TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion. , 2015, European heart journal.

[52]  M. Stratton,et al.  High burden and pervasive positive selection of somatic mutations in normal human skin , 2015, Science.

[53]  D. Butkiewicz,et al.  Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients , 2015, British Journal of Cancer.

[54]  E. Zeggini,et al.  Leukemia-Associated Somatic Mutations Drive Distinct Patterns of Age-Related Clonal Hemopoiesis , 2015, Cell reports.

[55]  M. Kessel,et al.  Endothelial p53 Deletion Improves Angiogenesis and Prevents Cardiac Fibrosis and Heart Failure Induced by Pressure Overload in Mice , 2015, Journal of the American Heart Association.

[56]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[57]  Christopher A. Miller,et al.  The Role of TP53 Mutations in the Origin and Evolution of Therapy-Related AML , 2014, Nature.

[58]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[59]  Joshua F. McMichael,et al.  Age-related cancer mutations associated with clonal hematopoietic expansion , 2014, Nature Medicine.

[60]  Aviv Regev,et al.  Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing , 2014, Nature Biotechnology.

[61]  Jan Vijg,et al.  Somatic mutations, genome mosaicism, cancer and aging. , 2014, Current opinion in genetics & development.

[62]  Zhaomin Li,et al.  Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. , 2014, Blood.

[63]  C. Mason,et al.  Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo , 2013, The Journal of experimental medicine.

[64]  C Haferlach,et al.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.

[65]  H. Aburatani,et al.  Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations. , 2013, The Journal of clinical investigation.

[66]  P. Bushel,et al.  p53 integrates host defense and cell fate during bacterial pneumonia , 2013, The Journal of experimental medicine.

[67]  Matthew D. Schultz,et al.  Epigenomic Analysis of Multilineage Differentiation of Human Embryonic Stem Cells , 2013, Cell.

[68]  S. Bojesen,et al.  Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population , 2013, British journal of haematology.

[69]  Peter Donnelly,et al.  Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer , 2012, Nature.

[70]  T. Sauka-Spengler,et al.  DNA methyltransferase3A as a molecular switch mediating the neural tube-to-neural crest fate transition. , 2012, Genes & development.

[71]  Zhigang Xue,et al.  Dnmt3a regulates both proliferation and differentiation of mouse neural stem cells , 2012, Journal of neuroscience research.

[72]  Mithat Gonen,et al.  Recurrent Somatic TET2 Mutations in Normal Elderly Individuals With Clonal Hematopoiesis , 2012, Nature Genetics.

[73]  Iannis Aifantis,et al.  ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. , 2012, Cancer cell.

[74]  E. Moding,et al.  p53 Functions in Endothelial Cells to Prevent Radiation-Induced Myocardial Injury in Mice , 2012, Science Signaling.

[75]  Joshua F. McMichael,et al.  The Origin and Evolution of Mutations in Acute Myeloid Leukemia , 2012, Cell.

[76]  William Wheeler,et al.  Detectable clonal mosaicism and its relationship to aging and cancer , 2012, Nature Genetics.

[77]  H. Hasselbalch,et al.  Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? , 2012, Blood.

[78]  M. Kaplan,et al.  DNA methyltransferase 3a limits the expression of interleukin-13 in T helper 2 cells and allergic airway inflammation , 2011, Proceedings of the National Academy of Sciences.

[79]  J. Berg,et al.  Dnmt3a is essential for hematopoietic stem cell differentiation , 2011, Nature Genetics.

[80]  Wenyong Zhang,et al.  Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. , 2011, Blood.

[81]  Yang Wang,et al.  Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA , 2011, Science.

[82]  Chuan He,et al.  Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine , 2011, Science.

[83]  Allon M. Klein,et al.  Universal patterns of stem cell fate in cycling adult tissues , 2011, Development.

[84]  O. Abdel-Wahab,et al.  Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. , 2011, Cancer cell.

[85]  P. Opolon,et al.  TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. , 2011, Cancer cell.

[86]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[87]  C. Schumann,et al.  Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  S. Bojesen,et al.  The JAK2 V617F somatic mutation, mortality and cancer risk in the general population , 2011, Haematologica.

[89]  H. Kantarjian,et al.  Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond , 2011, Nature Reviews Drug Discovery.

[90]  I. Komuro,et al.  Promotion of CHIP-Mediated p53 Degradation Protects the Heart From Ischemic Injury , 2010, Circulation research.

[91]  R. Medzhitov,et al.  p53-mediated hematopoietic stem and progenitor cell competition. , 2010, Cell stem cell.

[92]  W. Nelson,et al.  Identification of DNA Methyltransferase 3a as a T Cell Receptor-Induced Regulator of Th1 and Th2 Differentiation1 , 2009, The Journal of Immunology.

[93]  David R. Liu,et al.  Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1 , 2009, Science.

[94]  E. Abraham,et al.  p53 Attenuates Lipopolysaccharide-Induced NF-κB Activation and Acute Lung Injury 1 , 2009, The Journal of Immunology.

[95]  L. Zon,et al.  Hematopoiesis: An Evolving Paradigm for Stem Cell Biology , 2008, Cell.

[96]  K. Sunagawa,et al.  Targeted deletion of p53 prevents cardiac rupture after myocardial infarction in mice. , 2006, Cardiovascular research.

[97]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[98]  L. Chan,et al.  Macrophage-Specific p53 Expression Plays a Crucial Role in Atherosclerosis Development and Plaque Remodeling , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[99]  Eric J Topol,et al.  Prevalence of conventional risk factors in patients with coronary heart disease. , 2003, JAMA.

[100]  M. Fiscella,et al.  Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[101]  D. Gilliland,et al.  Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. , 1996, Blood.